NASDAQ:RETA - Reata Pharmaceuticals Stock Price, Forecast & News

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Reata Pharmaceuticals Inc (NASDAQ:RETA) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.25) by $0.07. The business earned $8.24 million during the quarter, compared to the consensus estimate of $7.43 million. Reata Pharmaceuticals had a negative return on equity of 3,281.61% and a negative net margin of 398.84%. The company's revenue for the quarter was up 59.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.07) earnings per share. View Reata Pharmaceuticals' Earnings History.

Reata Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Reata Pharmaceuticals.

8 equities research analysts have issued 12 month price objectives for Reata Pharmaceuticals' shares. Their forecasts range from $130.00 to $328.00. On average, they anticipate Reata Pharmaceuticals' share price to reach $255.63 in the next year. This suggests a possible upside of 27.1% from the stock's current price. View Analyst Price Targets for Reata Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Reata Pharmaceuticals.

Headlines about RETA stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Reata Pharmaceuticals earned a news impact score of -1.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Reata Pharmaceuticals.

Reata Pharmaceuticals saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 3,150,000 shares, a decline of 6.0% from the October 31st total of 3,350,000 shares. Based on an average daily volume of 442,600 shares, the days-to-cover ratio is presently 7.1 days. Currently, 13.7% of the shares of the stock are sold short. View Reata Pharmaceuticals' Current Options Chain.

Some companies that are related to Reata Pharmaceuticals include GRIFOLS S A/S (GRFS), UCB (UCBJF), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Beigene (BGNE) and Jazz Pharmaceuticals (JAZZ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Archrock (AROC), Targa Resources (TRGP), Precision Drilling (PD) and Sangamo Therapeutics (SGMO).

(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

Reata Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (1.54%), Point72 Asset Management L.P. (1.20%), Emerald Advisers LLC (0.94%), Emerald Mutual Fund Advisers Trust (0.89%), Alta Advisers Ltd (0.53%) and Rice Hall James & Associates LLC (0.36%). Company insiders that own Reata Pharmaceuticals stock include Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson, Keith Wayne Ward and R Kent Mcgaughy Jr. View Institutional Ownership Trends for Reata Pharmaceuticals.

RETA stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Squarepoint Ops LLC, Columbus Circle Investors, WCM Investment Management LLC, Rice Hall James & Associates LLC, P.A.W. Capital Corp and Strs Ohio. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos, James Edward Bass, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward. View Insider Buying and Selling for Reata Pharmaceuticals.

RETA stock was bought by a variety of institutional investors in the last quarter, including Alta Advisers Ltd, Point72 Asset Management L.P., Virtu Financial LLC, State Street Corp, First Trust Advisors LP, California Public Employees Retirement System, BBVA USA Bancshares Inc. and Dupont Capital Management Corp. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass, James W Traweek Jr and R Kent Mcgaughy Jr. View Insider Buying and Selling for Reata Pharmaceuticals.

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RETA stock can currently be purchased for approximately $201.05.

Reata Pharmaceuticals has a market capitalization of $6.09 billion and generates $53.59 million in revenue each year. The company earns $-80,550,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis. Reata Pharmaceuticals employs 123 workers across the globe.View Additional Information About Reata Pharmaceuticals.

The official website for Reata Pharmaceuticals is http://www.reatapharma.com/.

Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]